Oral Cancer Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Oral Cancer Treatment Market is Segmented By Type (Squamous Cell Carcinoma, Verrucous Carcinoma, Minor Salivary Gland Carcinomas, Lymphomas, Others), By Treatment (Targeted Therapy, Chemotherapy, Immunotherapy), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Oral Cancer Treatment Market Size

The Global Oral Cancer Treatment Market reached USD 1.9 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 2.8 billion by 2030. The global oral cancer treatment market is expected to exhibit a CAGR of 5.1% during the forecast period 2023-2030.  The global oral cancer treatment market has grown significantly in recent years and is projected to continue on its upward trend.

The market is currently going through a period of significant change that is being fueled by a number of trends, such as the increasing focus on personalized medicine, the rise of immunotherapy, and technological advancements in radiation therapy.

Furthermore, the increasing prevalence of oral cancer, the increasing need for targeted therapies, and the growing consumption of tobacco-containing products such as cigarettes are driving up the size of the oral cancer treatment market. Due to growing oral cancer awareness initiatives and early detection schemes, the market is seeing an increase in demand from North American regions. 

Oral Cancer Treatment Market Scope

To Know More Insights - Download Sample
 

Oral Cancer Treatment Market Dynamics

Increasing Prevalence of Oral Cancer to Drive the Growth of the Oral Cancer Treatment Market

The rising global incidence of oral cancer is the primary driver of the oral cancer treatment market's growth. Tobacco and alcohol consumption, human papillomavirus (HPV) infection, and bad lifestyle behaviors all contribute to the rising prevalence of oral cancer. This fosters market expansion by increasing demand for effective treatment options. 

For instance, according to American Society of Clinical Oncology (ASCO) report of 2023, in the United States, about 54,540 persons are expected to be diagnosed with oral or oropharyngeal cancer, with men accounting for 39,290 cases and women accounting for 15,250 cases in 2023. The number of people diagnosed with oral or oropharyngeal cancer worldwide in 2020 is expected to reach 476,125. Notably, men had more than double the incidence rates of these malignancies as women, indicating a major gender discrepancy in the frequency of these diseases.

Advancements in Treatment will Drive the Demand for Oral Cancer Treatment Market

Advances in treatment options for oral cancer have significantly transformed patient care, such as targeted therapies and immunotherapies, and have transformed the management of oral cancer. These innovative drug therapies boost efficacy, reduce adverse effects, and improve patient outcomes.

The advancements of targeted therapies such as cetuximab, a monoclonal antibody, target and inhibit the epidermal growth factor receptor (EGFR) protein, which may be present in some oral cavity and oropharyngeal malignancies. Treatment with them produces significantly greater response rates than immunotherapy because they are more targeted and have validated biomarkers of response. Thus, increasing advancements will drive the growth of the global oral cancer treatment market.

High Cost of  Treatment will Hamper the Growth of the Market

The high expense of oral cancer treatment, including immunotherapy and chemotherapy, is a substantial barrier for patients, particularly in developing countries. Furthermore, certain treatments include surgery in addition to medicine, and the costs involved with several treatment sessions, medications, and supportive care can create financial challenges, limiting access to optimal treatment alternatives. This slows the uptake of advanced medicines and has an impact on market growth overall.

Oral Cancer Treatment Market Segment Analysis

The global oral cancer treatment market is segmented based on type, treatment, distribution channel, and region.

Owing to its Effectiveness, the Chemotherapy Segment Accounted for Approximately 45.1% of the Oral cancer treatment Market Share

Chemotherapy segment is expected to dominate the global oral cancer treatment market due to its broad application, comprehensive treatment approach, established use, and continuous research and development. It is commonly used as the main treatment, adjuvant therapy, or palliative care for oral cancer. Chemotherapy, in conjunction with surgery and radiation therapy, is a multimodal therapeutic approach. The most commonly used chemotherapy drugs are cisplatin and fluorouracil (5FU).

The ongoing research strives to improve chemotherapeutic medications, delivery techniques, and treatment regimens, assuring the drug's continued significance in the area. According to the findings of a phase 2/3 trial (CTRI/2017/05/008700), radiation plus docetaxel improved disease-free survival (DFS) and overall survival (OS) compared to radiation alone in patients with head and neck squamous cell carcinoma (HNSCC) unsuitable for cisplatin-based chemoradiation. Thus owing to the above factors, the segment will dominate over the forecast period.

Source: DataM Intelligence Analysis (2023)

Oral Cancer Treatment Market Geographical Share

North America Accounted for Approximately 41.4% of the Market Share in 2022, Owing to Technological Advancements and Better Government Initiatives

North America's dominance in the worldwide oral cancer treatment market is supported by a large number of clinical trials and approvals by universities and research institutions. The region's excellent research infrastructure, strong collaboration networks, stringent regulatory approvals, access to finance, and leading treatment recommendations all contribute to its prominent position. Universities and institutes in North America actively push innovation, expand treatment alternatives, and translate research findings into clinical practice.

For instance, the Medical University of South Carolina is conducting a clinical trial in which topically administered Aldara is being studied for its impact on people with oral cancer. Aldara stimulates the toll-like receptor (TLR) in oral cancer cells, causing the tumor cells to self-destruct. It also activates immune cells to attack and destroy cancer cells. While Aldara is already FDA-approved for the treatment of skin and melanoma, its usage in this trial is considered "off-label" because it is being investigated for the treatment of mouth cancer. Currently, this trial is under phase 1 and the estimated completion of this trial is September 2023. Hence, owing to the above factors, the market is expected to witness growth over the forecast period.

Source: DataM Intelligence Analysis (2023)

Oral Cancer Treatment Market Companies

The major global players in the oral cancer treatment market include Novartis AG, Hospira, Inc., Teva Pharmaceutical Industries Ltd, Pfizer Inc., Lilly USA, LLC, Merck & Co., Inc., Fresenius Kabi AG, Accord BioPharma, Inc., Bristol-Myers Squibb Company, and Spectrum Pharmaceuticals, Inc., among others. 

COVID-19 Impact on Oral Cancer Treatment Market

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has had significant impacts on the global market for oral cancer treatment. It has disrupted healthcare infrastructure, hampered treatment access in afflicted areas, caused economic instability, disrupted international cooperation, and altered market dynamics. 

Damaged healthcare facilities, restricted mobility, financial constraints, delayed diagnosis, and hampered research and development activities are among the repercussions of the conflict. These factors affect the availability and quality of oral cancer therapy collectively, illustrating the war's far-reaching repercussions for healthcare systems and patient outcomes.

By Type

• Squamous Cell Carcinoma
• Verrucous Carcinoma
• Minor Salivary Gland Carcinomas
• Lymphomas
• Others

By Treatment

• Targeted Therapy
• Chemotherapy
• Immunotherapy

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• On April 16, 2023, Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology, and other major diseases, announced the release of the final analysis results of ORIENT-15, the Phase 3 study evaluating sintilimab in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma (ESCC).
• On June 30, 2022, Novartis announced Phase III RATIONALE 306 trial results showing that tislelizumab plus chemotherapy improved overall survival (OS) as a first-line treatment for adult patients with unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status.
• On September 2, 2022, clinical researchers at the VA Greater Los Angeles Healthcare System, in collaboration with the Sylvester Comprehensive Cancer Centre at the University of Miami Miller School of Medicine, began a phase 2 clinical trial for Naturally-Derived Drug Lozenge Shows Promising Results and Safety in Combating Oral Cancer.

Why Purchase the Report?

• To visualize the global oral cancer treatment market segmentation based on type, treatment, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of oral cancer treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global oral cancer treatment market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies